- (CBS/AP) A new rheumatoid arthritis drug considered to be the first of its kind got backed by a Food and Drug Administration (FDA) advisory panel Wednesday, putting the drug a step closer to hitting the market. (CBS News)
- SILVER SPRING, Md., May 9 (Reuters) - Pfizer Inc won support from a U.S. advisory panel on Wednesday for its arthritis drug, which the worlds top drugmaker hopes will give it a major boost after a wave of patent expiries. (Huffington Post)
- Pfizer Inc. (NYSE:PFE) announced today that the Arthritis Advisory Committee to the U.S. (PharmiWeb)
- SILVER SPRING, Md. -- An FDA advisory committee has voted 8-2 in favor of recommending approval of the oral JAK inhibitor tofacitinib for the treatment of rheumatoid arthritis. (MedPage Today)
- This article is provided to FT.com readers by BioPharm Insight—a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market. www.biopharminsight. (Financial Times)
- SILVER SPRING, MD. – There soon may be a new oral disease-modifying antirheumatic drug in town, the first in more than 10 years to be approved for the treatment of rheumatoid arthritis. (familypracticenews.com)
- May 9, 2012 — The US Food and Drug Administration Arthritis Advisory Committee voted 8-2 today to recommend the approval of tofacitinib, the first oral drug to treat rheumatoid arthritis. (Medscape News)
- A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety. (New York Times)
- Tofacitinib, taken orally, could serve as an alternative approach to treating moderate to severe patients who did not respond to one or more traditional therapies, said the advisory committee. (medicalxpress.com)
Thursday, May 10, 2012
Tofacitinib
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment